



## ADULT VENOUS THROMBOEMBOLISM PROPHYLAXIS ASSESSMENT AND ORDER SHEET

STEP 1: Obtain Ris	STEP 1: Obtain Risk Factor Score (RFS)							
Use the assessment on reverse side ENTER RFS SCORE IN BOX:								
RFS	0-1	2	3-4	Greater t	han 4			
RISK LEVEL	LOW	MODERATE	HIGH	VERY H	IGH			
STEP 2: Does patient have a contraindication to pharmacologic prophylaxis (see below): Yes: Use non-pharmacologic therapy and re-evaluate for pharmacologic prophylaxis on a daily basis. No: Therapy should be based on the risk factor score above								
CONTRAINDICATIONS / CAUTION USING PHARMACOLOGIC PROPHYLAXIS								
<ul> <li>Contraindication to pharmacologic therapy based on clinical judgment (Reason)</li> <li>Patient presently on therapeutic anticoagulation</li> <li>ABSOLUTE CONTRAINDICATIONS</li> <li>Active bleeding from wounds, drains, lesions (within 24-48h)</li> <li>Warfarin use in pregnancy</li> <li>Heparin use with history of Heparin-induced thrombocytopenia</li> <li>Known hypersensitivity to Heparin or pork products</li> <li>Use CAUTION when anticoagulants are used in patients with: (Specialty consultation should be considere</li> <li>Cerebral hemorrhage at any time previously</li> <li>Craniotomy past 2 weeks</li> <li>GI, GU bleed or hemorrhagic stroke within past 6 months</li> <li>Active Intracranial lesions/ neoplasms</li> <li>Diabetic retinopathy</li> <li>Recent intraocular/spinal/intracrainial surgery</li> <li>Bacterial endocarditis</li> <li>Planned elective surgery using neuroaxial anesthesia</li> <li>Hypertensive crisis</li> <li>Severe trauma or surgery to head, spinal cord, or</li> <li>Thrombocytopenia</li> <li>Vascular access/biopsy sites inaccessible to hemostatic control</li> <li>Spinal Tap &lt;12h</li> </ul>								
<ul> <li>□ Vascular access/biopsy sites inaccessible to hemostatic control</li> <li>□ Presence or planned epidural / spinal catheter (see reverse)</li> <li>□ Use of tPA within 24 hrs or GPIIb/Illa inhibitor &lt; 24 hrs</li> </ul>								
✓ RISK LEVEL:		ORDERS	:		RN Init.			
□ NON-	Early aggressive mobilization							
PHARMACOLOGIC	GEC (graduated elastic compression) to bilateral Left only Right only							
THERAPY	□ SCDs to □ bilateral lower extremities □ Left only □ Right only							
LOW RISK								
(RFS 0-1)	GEC (graduated elastic compression) to bilateral Left only Right only							
	SCDs to bilateral lower extremities Left only Right only							
	<ul> <li>Early aggressive mobilization</li> <li>Heparin 5000 units SC Q 8 hours</li> <li>OR Q 12 hours</li> </ul>							
(RFS 2)								
_								
	<ul> <li>Early aggressive mobilization</li> <li>GEC (graduated elastic compression) to  bilateral  Left only  Right only</li> </ul>							
(RFS 3-4)								
	□ SCDs to □ bilateral lower extremities □ Left only □ Right only							
(RFS > 4)	(RFS > 4) Consider Pharmacologic □ Enoxaparin 30 mg SC Q 12 hrs <u>OR</u> □ Enoxaparin 40 mg SC Q 24 hrs							
<ul> <li>+ Mechanical Prophylaxis Warfarinmg PO X1 (target INR of 1.8-2.4)</li> <li>Warfarin to be ordered daily (Prophylaxis for Orthopedic pts. ONLY)</li> </ul>								
			<u> </u>					
LABORATORY:	<ul> <li>□ CBC 24 hours after initiation of pharmacologic therapy, then every other day (for 14 days when Heparin or LMWH is used)</li> <li>□ Baseline PT/ INR (REQUIRED if Warfarin is used)</li> </ul>							
MD/LIP/NP Signature:		IDa	#: Date:	Time:				
Nurse Signature:		ID;	#: Date:	Time:				





# ADULT VENOUS THROMBOEMBOLISM PROPHYLAXIS ASSESSMENT AND ORDER SHEET

RISK FACTOR SCORE (RFS) ASSESSMENT Check (✓) Applicable up to 5 points							
1 point EACH	2 points EACH	3 points EACH	5 points EACH				
Age 41-59       AMI < 1 mo	<ul> <li>Age 60-74</li> <li>BMI &gt; 35</li> <li>Surgery 1-2 Hrs and/or arthroscopic, laparoscopic of any duration</li> <li>Anticipated immobility &gt; 24 h (bedrest)</li> </ul>	<ul> <li>Age 75 +</li> <li>BMI &gt; 50</li> <li>Surgery 2-3 Hrs</li> <li>Unprovoked superficial thrombophlebitis</li> <li>Prior DVT or PE</li> <li>Family history DVT/PE</li> <li>Malignancy and/or treatment</li> <li>Hypercoagulable state*:</li> <li>Positive Factor V Leiden</li> <li>Positive Prothrombin variant 20210A</li> <li>Positive Iupus anticoagulant</li> <li>Antithrombin III deficiency</li> <li>Protein C or S deficiency</li> <li>Elevated anticardiolipin antibody</li> <li>Elevated Factor VIII</li> <li>Other thrombophilia</li> </ul>	<ul> <li>Surgery &gt;3 Hrs</li> <li>Elective major lower extremity arthroplasty</li> <li>Hip, Pelvic or long bone fracture &lt; 1 mo</li> <li>Recent stroke &lt; 1 mo</li> <li>Multiple Trauma &lt; 1 mo</li> <li>Acute spinal cord injury (SCI) &lt; 1 mo</li> </ul>				
Total Points	Total Points	Total Points	Total Points				
TOTAL RISK FACTOR SCORE (Add the values from each column for the total score)							
SPECIAL CONSIDERATIONS: *Consider SBUMC VTE Team consult for hypercoagulable states							
Renal impairment:       Use low molecular weight heparin with caution in patients with Cr > 2 or CrCL < 30 mL/min.							

Platelet counts that drop greater than 50% from baseline and/or less than 100,000: consider workup for Heparin Induced Thrombocytopenia

# Recommendations for the Use of Antithrombotic Prophylaxis in Patients with Epidural Catheters / Spinal Catheters / Spinal Anesthesia / Lumbar Puncture (Spinal Tap)

For patients receiving low does SQ unfractionated heparin (5,000 units):

- > Concurrent use of epidural or spinal catheter and SQ dose unfractionated heparin IS NOT CONTRAINDICATED. \*Note
- SQ Heparin can begin immediately after placing epidural/spinal catheter
- Ensure an adequate platelet count if on heparin.

### For patients receiving prophylactic doses of Low Molecular Weight Heparin:

- Before placing or removing a catheter or performing a neuraxial block WAIT 10-12 hours after a prophylactic dose of low molecular weight heparin is given
- > Single daily dosing is <u>NOT</u> contraindicated with an epidural catheter in place.
- ▶ If twice daily dosing is done, an epidural catheter cannot be placed for 24 hours after last dose.
- > Initiate low molecular weight heparin thromboprophylaxis a minimum of 2 hours after removal of the catheter.
- For patients needing anti-inflammatory medications, the use of cyclooxygenase-2 specific inhibitor (celecoxib) is recommended as this medication has minimal effect on platelet function.
- Antiplatelet or oral anticoagulant medications administered in combination with LMWH may increase the risk of spinal hematoma. Concomitant administration of medications affecting hemostasis, such as antiplatelet drugs, standard heparin, or dextran represents an additional risk of hemorrhagic complications perioperatively, including spinal hematoma.

#### For patients receiving warfarin:

> Neuraxial catheters should NOT be removed until the INR is < 1.5.